1. Scrip
  2. >>Therapy Areas
  3. >>Sensory

Astellas’ Izervay Joins Geographic Atrophy Market, Intensifying Competition

 
• By Jessica Merrill

The C5 inhibitor, recently acquired by Astellas, will be commercially available in two to four weeks and will compete against Apellis Pharma’s Syfovre.

competitive edge
Astellas hopes to have a competitive edge over Apellis in geographic atrophy • Source: Shutterstock

Astellas Pharma, Inc.’s Izervay (avacincaptad pegol intravitreal solution) is the second drug approved in the US for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in six months, following the US Food and Drug Administration’s approval of Apellis Pharmaceuticals, Inc.’s Syfovre (pegcetacoplan injection) in February, and will test the early commercial traction that Apellis has reached.

Key Takeaways
  • Astella’s Pharma’s Izervay is the second drug newly approved for geographic atrophy.
  • Izervay will compete against Apellis’ Pharmaceuticals’ Syfovre, which launched in February.
  • The approval of Izervay follows Astella’s acquisition of Iveric Bio in July

The two drugs are the first approved for geographic atrophy and are competing for share in the potentially multi-billion-dollar market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

 
• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.

Outlook Holds Out Hope For Wet AMD Approval Despite Phase III Topline Miss

 
• By Alaric DeArment

The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.

GSK’s Linerixibat GLISTENs In PBC Itching

 
• By Elizabeth Cairns

But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.

More from Therapy Areas